Company Profile

RAKSHIT DRUGS PVT LTD
Year Established : 2000
Total Assets(USD) : 500,000 to 99,999,999
Total Number of Staff : more than 1000
Main Competitive Advantages : Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service
  • Contact Person :
  • Fax:

We Rakshit Drugs Pvt. Ltd, Rakshit Pharmaceuticals Ltd & Azico-Biophore India Pvt. Ltd  are a group of companies having 6 cGMP compliance API manufacturing facilities.

Regulatory status : USFDA Approved,  EUGMP Approved, CEP Approved Products, Japan PMDA Accreditation, Brazil ANVISA approved, Mexico COFEPRIS, Korea MFDS approved, WHO GMP, Written Confirmation.

Veterinary APIs:

Albendazole, Buparvaquone ,Butaphosphan, Clorsulon, Enrofloxacin, Flunixin Meglumine, Triclabendazole

Human APIs:

Albendazole, Amlodipine Besylate, Avanafil, Azathioprine, Brinzolamide, Citicoline Sodium, Cinnarizine, Dapaglifozin, Dapoxetine, Diacerein, Famotidine, Flibanserin, Glimepiride, Lacosamide, Levothyroxine sodium, Liothyronine sodium, Mycophenolate Mofetil & Sodium, Oseltamivir Phosphate, Pantoprazole Sodium & Magnesium, Sildenafil Citrate, Sodium Picosulfate , Sparfloxacin, Tadalafil, Trimetazidine , Udenafil , Valganciclovir & Vardenafil Hcl Trihydrate.

USDMF : Clorsulon, Famotidine, Pantoprazole Sodium , Pantoprazole Magnesium, Levothyroxine Sodium, Liothyronine Sodium, Oseltamivir Phosphate, Sildenafil Citrate,

CEP Approved: Sildenafil Citrate, Levothyroxine Sodium, Liothyronine Sodium, Pantoprazole Sodium, Tadalafil

CEP Under Review: Azathioprine, Mycophenolate Sodium, Famotidine, Oseltamivir Phosphate, Mycophenolate Mofetil, Triclabendazole

CEP Planned to file: Diacerein, Cinnarizine, Vardenafil Hcl Trihydrate, Sodium Picosulphate

For more details contact

Shailesh Agarwal

AGM - Marketing

Rakshit Group Of Companies

Email id: exports@rakshitpharma.com

 

PharmaSources Customer Service